| Mrs Becky Jo Dyer, MA CCC-SLP | |
|
2645 Smith Rd, Fairlawn, OH 44333-2805 | |
| (330) 664-4991 | |
| Not Available |
| Full Name | Mrs Becky Jo Dyer |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 2645 Smith Rd, Fairlawn, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073916060 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SP 2999 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Becky Jo Dyer, MA CCC-SLP 2645 Smith Rd, Fairlawn, OH 44333-2805 Ph: (330) 664-4991 | Mrs Becky Jo Dyer, MA CCC-SLP 2645 Smith Rd, Fairlawn, OH 44333-2805 Ph: (330) 664-4991 |
News Archive
A new genetic approach to treating sickle cell disease is showing promising results in mice, report researchers from Children's Hospital Boston. By inactivating a gene they previously discovered to be important in the laboratory, they were able to boost production of a healthy fetal form of hemoglobin in the mice, potentially compensating for the defective adult hemoglobin that causes red blood cells to "sickle" and obstruct blood flow.
Unless new treatments are found, it is predicted that more than 100 million people worldwide will be affected by Alzheimer's disease by 2050. With very few new drugs in the pipeline, researchers are exploring every possible avenue to treat the disease.
Robert "Buzz" Gehle thought the itchy rash he was experiencing was a recurrence of an earlier case of shingles. But when his doctor saw he was also jaundiced, he immediately knew there was a problem with Gehle's liver.
As flu season picks up steam across the country, it's important for people to be tested very early after symptoms that are compatible with influenza start, since there are effective treatments that can limit severe, life-threatening disease and curtail transmission to others.
Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, presented Phase 2 clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma (liver cancer, HCC).
› Verified 2 days ago
Mrs. Taylor Nicole Schell, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 150 N Miller Rd Ste 150a, Fairlawn, OH 44333 Phone: 330-867-2240 Fax: 330-867-2245 | |
Kristen Lee Bever, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 150 N Miller Rd Ste 150a, Fairlawn, OH 44333 Phone: 330-867-2240 Fax: 330-630-3198 | |
Isaac Sernoffsky, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 150 N Miller Rd Ste 150a, Fairlawn, OH 44333 Phone: 330-867-2240 Fax: 330-630-3198 | |
Kaitlin George, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 150 N Miller Rd Ste 150a, Fairlawn, OH 44333 Phone: 330-867-2240 Fax: 330-630-3198 | |
Laura Ray, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3428 W Market St, Fairlawn, OH 44333 Phone: 330-668-4041 | |
Brenna Dupratt, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 150 N Miller Rd Ste 150a, Fairlawn, OH 44333 Phone: 330-867-2240 Fax: 330-630-3198 |